In May 2023, the U.S. Court of Appeals for the Second Circuit ruled in favor of Purdue Pharma’s Chapter 11 Plan of Reorganization (the “Plan”), affirming the Bankruptcy Court’s September 2021 confirmation order and holding that the Plan is appropriate under the law. The case will be heard before the Supreme Court of the United States in December 2023. The Company’s Plan will deliver billions of dollars of value for victim compensation, opioid crisis abatement, and overdose rescue medicines. We continue to operate fully, honoring our existing relationships and meeting our obligations to our partners, customers, and consumers.
READ MORE HERE >
The health and safety of our colleagues, customers and community, along with the continuity of business operations – critical to serve patients who rely on our medicines and products – are our top priorities.
Our manufacturing facilities are open and operating but, where our workforce can work from home, they are doing so. We have taken special measures to protect those who continue to work on-site during this time, including enhanced cleaning, shift adjustments, social distancing, and business continuity planning, among other measures.
Our business remains open. Our products are available, and we have not identified any supply chain risks at this time. Please continue to contact us through your normal channels. Our medical team is available and if you have questions related to our products please contact us; 1-888-827-0618; Ask Adlon Medical. Other contact information can be found here.